Interaction study of pioglitazone with albumin by fluorescence spectroscopy and molecular docking.
Pioglitazone is a medicine of thiazolidinedione (TZD) class with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone binding to human serum albumin (HSA) was investigated at different temperatures (290, 300 and 310 K) by fluorescence spectroscopic method. Molecular docking study was also carried out besides the experiments. Experimental results revealed that pioglitazone have an ability to quench the intrinsic fluorescence of HSA tryptophan through a static quenching procedure. The binding constant was determined using Stern-Volmer modified equation and energy transfer mechanisms of quenching were discussed. Thermodynamic parameters were also calculated according to enthalpy changes dependence on different temperatures. According to the theoretical and experimental results, hydrogen bonding was found to play a major role in the interaction of pioglitazone with HSA.
Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Farnoush
F
Faridbod
Mohammad Reza
MR
Ganjali
Bagher
B
Larijani
Siavash
S
Riahi
Ali Akbar
AA
Saboury
Morteza
M
Hosseini
Parviz
P
Norouzi
Christoph
C
Pillip
D001665:Binding Sites; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D000077205:Pioglitazone; D012709:Serum Albumin / Q000378:metabolism*; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013056:Spectrophotometry, Ultraviolet; D013696:Temperature; D045162:Thiazolidinediones / Q000737:chemistry / Q000378:metabolism*
D012709:Serum Albumin; D045162:Thiazolidinediones; D000077205:Pioglitazone